Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 40,095,390 | 37,725,000 | 36,270,860 | 46,910,160 | 43,783,120 |
| Cost of Goods | 11,562,440 | 10,654,000 | 11,817,340 | 15,955,290 | 15,027,940 |
| Gross Profit | 28,532,950 | 27,071,000 | 24,453,510 | 30,954,880 | 28,755,180 |
| Operating Expenses | 23,394,950 | 18,680,890 | 16,496,880 | 22,428,160 | 18,762,750 |
| Operating Income | 5,138,436 | 8,390,105 | 7,956,978 | 8,526,995 | 9,993,372 |
| Interest Expense | 854,915 | 985,169 | 1,087,235 | 1,078,078 | 1,145,328 |
| Other Income | 159,737 | 138,074 | 91,530 | 34,377 | 98,868 |
| Pre-tax Income | 4,443,258 | 7,543,010 | 6,961,273 | 7,483,294 | 8,946,912 |
| Income Tax | 672,175 | 940,388 | 874,488 | 475,785 | 744,720 |
| Net Income Continuous | 3,771,083 | 6,602,621 | 6,086,785 | 7,007,510 | 8,202,192 |
| Net Income Discontinuous | N/A | N/A | 13,234,830 | N/A | N/A |
| Minority Interests | 480,490 | 472,682 | 822,539 | 977,696 | 820,476 |
| Net Income | $3,290,593 | $6,129,939 | $18,499,080 | $6,029,813 | $7,381,716 |
| EPS Basic Total Ops | 1.62 | 3.03 | 9.19 | 3.01 | 3.71 |
| EPS Basic Continuous Ops | 1.85 | 3.26 | 3.02 | 3.50 | 4.12 |
| EPS Basic Discontinuous Ops | N/A | N/A | 6.57 | N/A | N/A |
| EPS Diluted Total Ops | 1.59 | 2.98 | 9.06 | 3.01 | 3.66 |
| EPS Diluted Continuous Ops | 1.82 | 3.21 | 2.98 | 3.50 | 4.07 |
| EPS Diluted Discontinuous Ops | N/A | N/A | 6.48 | N/A | N/A |
| EPS Diluted Before Non-Recurring Items | 4.05 | 3.86 | 3.46 | 3.89 | 3.73 |
| EBITDA(a) | $8,398,360 | $11,243,610 | $10,612,600 | $8,526,996 | $13,012,050 |